Turing Biosystems Ltd

	Page
Balance Sheet	1—2
Notes to the Financial Statements	3—6

Registered number: 13773831

		2025		2024
	Notes	£	£	£	£
FIXED ASSETS
Tangible Assets	4		1,477		1,058
Investments	5		84		84

			1,561		1,142
CURRENT ASSETS
Debtors	6	122,998		113,596
Cash at bank and in hand		681,421		1,235,679

		804,419		1,349,275
Creditors: Amounts Falling Due Within One Year	7	(11,836 )		(31,706 )

NET CURRENT ASSETS (LIABILITIES)			792,583		1,317,569

TOTAL ASSETS LESS CURRENT LIABILITIES			794,144		1,318,711

NET ASSETS			794,144		1,318,711

CAPITAL AND RESERVES
Called up share capital	8		1,469		1,469
Share premium account			1,974,948		1,974,948
Profit and Loss Account			(1,182,273 )		(657,706 )

SHAREHOLDERS' FUNDS			794,144		1,318,711

Page 1

Page 2

Turing Biosystems Ltd

Balance Sheet (continued)

As At 30 November 2025

For the year ending 30 November 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board

Dr Remy Jean Adrien Boutonnet

Director

23 July 2026

The notes on pages 3 to 6 form part of these financial statements.

1. General Information

Turing Biosystems Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 13773831 . The registered office is 37 Cremer Street, Workspace Brickfields, Office 303, London, E2 8HD.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

2.2. Going Concern Disclosure

The directors have not identified any material uncertainties related to events or conditions that may cast significant doubt about the company's ability to continue as a going concern. Therefore the financial statements have been prepared on a going concern basis which assumes the Company will continue in operational existence for the foreseeable future.

The Company is involved in research and development activities and is working towards achieving a sustainable revenue generating activity. The directors have considered the basis of the financial statements and are satisfied that a combination of business growth and further investment commitments will enable the Company to meet its liabilities as they fall due.

2.3. Tangible Fixed Assets and Depreciation

Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Computer Equipment

3 years, straight line

2.4. Investments

Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value where the difference between cost and fair value is material. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.

2.5. Cash and Cash Equivalents

Cash and cash equivalents are basic financial assets and include cash in hand and deposits held at call with banks, other short-term highly liquid investments that mature in no more than three months from the date of acquisition and are readily convertible to a known amount of cash with insignificant risk of change in value, and bank overdrafts.

2.6. Financial Instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Basic financial assets

Basic financial assets, which include debtors and bank balances, are measured at transaction price including transaction costs.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, are recognised at transaction price including transaction costs.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities.

Page 3

Page 4

Turing Biosystems Ltd

Notes to the Financial Statements (continued)

For The Year Ended 30 November 2025

2.7. Foreign Currencies

Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the profit / loss before taxation.

2.8. Taxation

Tax is recognised in profit or loss except that a charge is attributable to an item of income and expense recognised as other comphrehensive income or to an item recognised directly in equity is also recognised in other comphrehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the company operates and generates income.

2.9. Pensions

The company operates a defined pension contribution scheme. Contributions are charged to the profit and loss account as they become payable in accordance with the rules of the scheme.

2.10. Research and Development

In the research phase of an internal project, it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives.

If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

3. Average Number of Employees

Average number of employees, including directors, during the year was: 3 (2024: 1)

4. Tangible Assets

	Computer Equipment
	£
Cost
As at 1 December 2024	2,282
Additions	1,481

As at 30 November 2025	3,763

Depreciation
As at 1 December 2024	1,224
Provided during the period	1,062

As at 30 November 2025	2,286

Net Book Value
As at 30 November 2025	1,477

As at 1 December 2024	1,058

Page 4

Page 5

Turing Biosystems Ltd

Notes to the Financial Statements (continued)

For The Year Ended 30 November 2025

5. Investments

	Subsidiaries
	£
Cost or Valuation
As at 1 December 2024	84

As at 30 November 2025	84

Provision
As at 1 December 2024	-

As at 30 November 2025	-

Net Book Value
As at 30 November 2025	84

As at 1 December 2024	84

Subsidiaries

Details of the company's subsidiaries as at 30 November 2025 are as follows:

Name of undertaking	Registered Office	Class of shares held	Direct holding	Indirect holding
Turing Biosystems SASU	France	Ordinary	100.00%	-

6. Debtors

	2025	2024
	£	£
Due within one year
Other debtors	3,720	-
Corporation tax recoverable assets	46,443	30,671
VAT	2,638	12,628
Other taxes and social security	-	20
Amounts owed by group undertakings	70,197	70,277

	122,998	113,596

7. Creditors: Amounts Falling Due Within One Year

	2025	2024
	£	£
Trade creditors	970	28,227
Other taxes and social security	4,593	-
Net wages	10	-
Other creditors	1,041	114
Accruals and deferred income	4,025	2,150
Directors' loan accounts	1,197	1,215

	11,836	31,706

Page 5

Page 6

Turing Biosystems Ltd

Notes to the Financial Statements (continued)

For The Year Ended 30 November 2025

8. Share Capital

	2025	2024
Allotted, called up and fully paid	£	£
1,000,000 Ordinary Shares of £ 0.001 each	1,000	1,000
468,766 Series Seed shares of £ 0.001 each	469	469

	1,469	1,469

Page 6